BACKGROUND: We have previously observed that donor bone marrow hematopoietic stem cells successfully induce transient mixed chimerism and renal allograft tolerance following non-myeloablative conditioning of the recipient. Stem cells isolated from the peripheral blood (PBSC) may provide similar benefits. We sought to determine the most effective method of mobilizing PBSC for this approach and the effects of differing conditioning regimens on their engraftment. METHODS: A standard dose (10 μg/kg) or high dose (100 μg/kg) of granulocyte colony-stimulating factor (GCSF) with or without stem cell factor (SCF) was administered to the donor, and PBSC were collected by leukapheresis. Cynomolgus monkey recipients underwent a nonmyeloablative conditioning regimen (total body irradiation, thymic irradiation, and ATG) with splenectomy (splenectomy group) or a short course of anti-CD154 antibody (aCD154) (aCD154 group). Recipients then received combined kidney and PBSC transplantation and a 1-mo post-transplant course of cyclosporine. RESULTS: Treatments with either two cytokines (GCSF+SCF) or high dose GCSF provided significantly more hematopoietic progenitor cells than standard dose GCSF alone. Recipients in the aCD154 group developed significantly higher myeloid and lymphoid chimerism (P < 0.0001 and P = 0.0002, respectively) than those in the splenectomy group. Longer term renal allograft survival without immunosuppression was also observed in the aCD154 group, while two of three recipients in the splenectomy group rejected their allografts soon after discontinuation of immunosuppression. CONCLUSIONS: Protocols including administration of two cytokines (GCSF + SCF) or high dose GCSF alone significantly mobilized more PBSC than standard dose GCSF alone. The recipients of PBSC consistently developed excellent chimerism and survived long-term without immunosuppression, when treated with CD154 blockade.
BACKGROUND: We have previously observed that donor bone marrow hematopoietic stem cells successfully induce transient mixed chimerism and renal allograft tolerance following non-myeloablative conditioning of the recipient. Stem cells isolated from the peripheral blood (PBSC) may provide similar benefits. We sought to determine the most effective method of mobilizing PBSC for this approach and the effects of differing conditioning regimens on their engraftment. METHODS: A standard dose (10 μg/kg) or high dose (100 μg/kg) of granulocyte colony-stimulating factor (GCSF) with or without stem cell factor (SCF) was administered to the donor, and PBSC were collected by leukapheresis. Cynomolgus monkey recipients underwent a nonmyeloablative conditioning regimen (total body irradiation, thymic irradiation, and ATG) with splenectomy (splenectomy group) or a short course of anti-CD154 antibody (aCD154) (aCD154 group). Recipients then received combined kidney and PBSC transplantation and a 1-mo post-transplant course of cyclosporine. RESULTS: Treatments with either two cytokines (GCSF+SCF) or high dose GCSF provided significantly more hematopoietic progenitor cells than standard dose GCSF alone. Recipients in the aCD154 group developed significantly higher myeloid and lymphoid chimerism (P < 0.0001 and P = 0.0002, respectively) than those in the splenectomy group. Longer term renal allograft survival without immunosuppression was also observed in the aCD154 group, while two of three recipients in the splenectomy group rejected their allografts soon after discontinuation of immunosuppression. CONCLUSIONS: Protocols including administration of two cytokines (GCSF + SCF) or high dose GCSF alone significantly mobilized more PBSC than standard dose GCSF alone. The recipients of PBSC consistently developed excellent chimerism and survived long-term without immunosuppression, when treated with CD154 blockade.
Authors: O Hartmann; A G Le Corroller; D Blaise; J Michon; I Philip; F Norol; M Janvier; J L Pico; M C Baranzelli; H Rubie; C Coze; A Pinna; V Méresse; E Benhamou Journal: Ann Intern Med Date: 1997-04-15 Impact factor: 25.391
Authors: T Kawai; A Poncelet; D H Sachs; S Mauiyyedi; S Boskovic; S L Wee; D S Ko; A Bartholomew; M Kimikawa; H Z Hong; G Abrahamian; R B Colvin; A B Cosimi Journal: Transplantation Date: 1999-12-15 Impact factor: 4.939
Authors: N Schmitz; D C Linch; P Dreger; A H Goldstone; M A Boogaerts; A Ferrant; H M Demuynck; H Link; A Zander; A Barge Journal: Lancet Date: 1996-02-10 Impact factor: 79.321
Authors: T Kawai; A B Cosimi; R B Colvin; J Powelson; J Eason; T Kozlowski; M Sykes; R Monroy; M Tanaka; D H Sachs Journal: Transplantation Date: 1995-01-27 Impact factor: 4.939
Authors: R G Andrews; R A Briddell; G H Knitter; T Opie; M Bronsden; D Myerson; F R Appelbaum; I K McNiece Journal: Blood Date: 1994-08-01 Impact factor: 22.113
Authors: J Beyer; N Schwella; J Zingsem; I Strohscheer; I Schwaner; H Oettle; S Serke; D Huhn; W Stieger Journal: J Clin Oncol Date: 1995-06 Impact factor: 44.544